Allink Biotherapeutics raises $47 million Series A extension to advance global ADC clinical programs from Shanghai base
Tuesday, December 16, 2025
Allink Biotherapeutics, a Shanghai-headquartered clinical-stage biotechnology company, has completed extension rounds of its Series A financing, securing a total of US$47 million to accelerate the development of its antibody-drug conjugate (ADC) and multi-specific antibody pipelines for oncology and immunology indications.[2] The round was led by existing backer Legend Capital alongside new investor Meituan Long-Z Investment, with participation from Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, Runzhang Venture Capital and other institutional investors.[2] This new capital injection underscores sustained investor confidence in China’s next-generation biologics innovation ecosystem and provides Allink Biotherapeutics with additional resources to advance its leading ADC assets through early global clinical development.
According to the company, proceeds from the Series A extension will primarily support two differentiated clinical-stage ADC programs that are already in global Phase I trials: ALK201 and ALK202.[2] ALK201 is described as a potential first- and best-in-class FGFR2b-targeted ADC, engineered to address solid tumors with FGFR2b overexpression.[2] Early clinical data have demonstrated encouraging efficacy signals across multiple tumor types, along with a favorable safety profile, supporting its development as a backbone therapy for biomarker-selected solid tumors.[2] The company intends to leverage these data to broaden the tumor spectrum and evaluate combination strategies that could position ALK201 in earlier treatment lines.
ALK202, the second lead asset, is an EGFR/cMET bispecific ADC aimed at overcoming resistance mechanisms seen with conventional EGFR-targeted therapies in non-small cell lung cancer (NSCLC) and other solid tumors.[2] Initial clinical observations have provided preliminary evidence that the bispecific design may translate into meaningful anti-tumor activity in biomarker-defined patient subsets.[2] Allink Biotherapeutics is now expanding ALK202 clinical development into additional tumor types characterized by EGFR and cMET dysregulation, reflecting a strategy to maximize clinical value across a broader range of indications. The company plans to adopt a biomarker-guided approach to patient selection for both ALK201 and ALK202, aligning with global precision oncology trends and enhancing the probability of regulatory and commercial success.
From an Asia-focused biopharma strategy perspective, Allink Biotherapeutics exemplifies a new generation of Chinese biotech companies building globally competitive ADC platforms while anchoring core R&D operations in the region. The expanded investor syndicate—combining established healthcare-focused funds and strategic growth capital—highlights continued appetite for differentiated modality platforms such as ADCs, despite a more selective funding environment. For regional pharma executives and R&D leaders, this financing signals ongoing capital support for advanced biologics arising from Shanghai’s innovation cluster, reinforcing the city’s role as a key ADC and multi-specific antibody hub within Asia.
Beyond its two lead clinical candidates, Allink Biotherapeutics is investing in platform innovation to sustain a long-term pipeline. The company is developing a proprietary masked T-cell engager (TCE) platform specifically engineered for solid tumors, an area where traditional TCEs have been constrained by safety and on-target off-tumor toxicity.[2] By incorporating tumor-selective activation mechanisms, the platform aims to extend TCE utility beyond hematologic malignancies into solid tumor indications that remain underserved by current immunotherapies. Simultaneously, the company is advancing a portfolio of first-in-class bi- and multi-specific antibody drug candidates in immunology, targeting complex disease pathways that may benefit from multi-target modulation.[2] These initiatives suggest that Allink Biotherapeutics is positioning itself not only as an ADC developer but as a broader biologics innovator with capabilities spanning conjugated antibodies, bispecifics, and T-cell engagers.
Allink Biotherapeutics’ leadership emphasized in the announcement that the fresh capital will enable efficient execution of a clear clinical roadmap, including global Phase I development, biomarker refinement, and preparation for pivotal trial readiness for its leading assets.[2] The company also indicated plans to initiate combination therapy studies for ALK201 and ALK202, integrating them with other standard-of-care or emerging agents to enhance therapeutic depth and durability of response in front-line patient populations.[2] For multinational and regional pharma partners evaluating ADC and multi-specific antibody collaborations, these developments create potential for co-development, licensing, or regional commercialization deals centered on Asia-discovered biologics. With dual focus on global clinical standards and China-based R&D efficiency, Allink Biotherapeutics’ US$47 million Series A extension illustrates how Asia’s oncology biotech sector is maturing towards globally relevant, platform-driven business models, aligning with strategic interests of investors, drug manufacturers, and healthcare stakeholders across the region.
